AR059032A1 - Combinacion de derivados de triazina y sensibilizadores de insulina - Google Patents

Combinacion de derivados de triazina y sensibilizadores de insulina

Info

Publication number
AR059032A1
AR059032A1 ARP070100138A ARP070100138A AR059032A1 AR 059032 A1 AR059032 A1 AR 059032A1 AR P070100138 A ARP070100138 A AR P070100138A AR P070100138 A ARP070100138 A AR P070100138A AR 059032 A1 AR059032 A1 AR 059032A1
Authority
AR
Argentina
Prior art keywords
alkoxy
alkyl
aryl
halogen
optionally substituted
Prior art date
Application number
ARP070100138A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Cravo
Didier Mesangeau
Gerard Moinet
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR059032A1 publication Critical patent/AR059032A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP070100138A 2006-01-13 2007-01-12 Combinacion de derivados de triazina y sensibilizadores de insulina AR059032A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0600344A FR2896159B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.

Publications (1)

Publication Number Publication Date
AR059032A1 true AR059032A1 (es) 2008-03-12

Family

ID=36654309

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100138A AR059032A1 (es) 2006-01-13 2007-01-12 Combinacion de derivados de triazina y sensibilizadores de insulina

Country Status (22)

Country Link
US (2) US8791115B2 (enExample)
EP (1) EP1971330B1 (enExample)
JP (1) JP5249782B2 (enExample)
KR (2) KR20140033498A (enExample)
CN (1) CN101355933A (enExample)
AR (1) AR059032A1 (enExample)
AT (1) ATE476179T1 (enExample)
AU (1) AU2006334734B2 (enExample)
BR (1) BRPI0620985B8 (enExample)
CA (1) CA2640897C (enExample)
CY (1) CY1110789T1 (enExample)
DE (1) DE602006016014D1 (enExample)
DK (1) DK1971330T3 (enExample)
EA (1) EA015576B1 (enExample)
ES (1) ES2347177T3 (enExample)
FR (1) FR2896159B1 (enExample)
IL (1) IL192558A (enExample)
PL (1) PL1971330T3 (enExample)
PT (1) PT1971330E (enExample)
SI (1) SI1971330T1 (enExample)
WO (1) WO2007079917A2 (enExample)
ZA (1) ZA200806947B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
JP5667985B2 (ja) * 2008-12-12 2015-02-12 ポクセル インスリンとトリアジンの組合せ及び糖尿病を治療するためのその使用
CA2745854A1 (en) * 2008-12-12 2010-06-17 Daniel Cravo Tetrahydrotriazine compounds for treating diseases associated with ampk activity
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
KR20120011667A (ko) 2010-07-29 2012-02-08 광주과학기술원 당뇨병 치료제의 스크리닝 방법
KR101271218B1 (ko) * 2012-12-07 2013-06-07 광주과학기술원 당뇨병 치료제의 스크리닝 방법
JP2020536121A (ja) 2017-10-02 2020-12-10 ポクセルＰｏｘｅｌ 駆出率が保持された心不全を治療する方法
CA3102412A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
WO2019238647A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US5885980A (en) * 1996-06-25 1999-03-23 Enrique G. Gutierrez Composition and method for treating diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
AU2001257456B2 (en) * 2000-05-01 2006-02-09 Aeropharm Technology, Inc. A core formulation
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
TW200526678A (en) * 2003-08-01 2005-08-16 Janssen Pharmaceutica Nv Substituted indole-O-glucosides
FR2863484B1 (fr) * 2003-12-11 2007-04-13 Oreal Utilisation de composes capables d'agir sur la voie metabolique controlee par la dopachrome tautomerase trp-2 comme agent protecteur des melanocytes du follicule pileux et applications
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.

Also Published As

Publication number Publication date
WO2007079917A3 (en) 2007-08-30
EP1971330A2 (en) 2008-09-24
BRPI0620985B1 (pt) 2020-04-28
JP5249782B2 (ja) 2013-07-31
FR2896159A1 (fr) 2007-07-20
CY1110789T1 (el) 2015-06-10
US8791115B2 (en) 2014-07-29
ATE476179T1 (de) 2010-08-15
ES2347177T3 (es) 2010-10-26
WO2007079917A2 (en) 2007-07-19
BRPI0620985B8 (pt) 2021-05-25
DK1971330T3 (da) 2010-10-25
PL1971330T3 (pl) 2011-01-31
JP2009523142A (ja) 2009-06-18
SI1971330T1 (sl) 2010-11-30
IL192558A (en) 2013-04-30
EA015576B1 (ru) 2011-10-31
BRPI0620985A2 (pt) 2011-11-29
AU2006334734A1 (en) 2007-07-19
KR20140033498A (ko) 2014-03-18
KR101482685B1 (ko) 2015-01-14
PT1971330E (pt) 2010-09-09
EP1971330B1 (en) 2010-08-04
CN101355933A (zh) 2009-01-28
CA2640897A1 (en) 2007-07-19
CA2640897C (en) 2015-10-20
FR2896159B1 (fr) 2008-09-12
EA200801676A1 (ru) 2008-12-30
US20140050786A1 (en) 2014-02-20
AU2006334734B2 (en) 2012-07-19
US20100285117A1 (en) 2010-11-11
ZA200806947B (en) 2009-11-25
KR20080088630A (ko) 2008-10-02
DE602006016014D1 (de) 2010-09-16

Similar Documents

Publication Publication Date Title
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
AR059030A1 (es) Combinacion de derivados de triazina y estimuladores de la secrecion de insulina
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
UY27666A1 (es) Nuevos derivados de piridina y quinolina
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR059031A1 (es) Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasa
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR066583A1 (es) Derivados de 3,3-espiroindolinona
ECSP088593A (es) 5-(arilsulfonil)-pirazolopiperidinas
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR062110A1 (es) Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico
AR044078A1 (es) Dihidroquinazolinas sustituidas
AR060914A1 (es) Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico.
AR045388A1 (es) Inhibidores del c-kit imidazopiridinicos n3-sustituidos
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR055959A1 (es) Derivados espiro para la modulacion de actividad de crth2
AR072793A1 (es) Compuestos de aril isoxazol con actividades antitumorales

Legal Events

Date Code Title Description
FB Suspension of granting procedure